Summary:
Pacific Research Partners is conducting a research study that investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.
Qualified Participants Must:
• Have a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration
•
Have a verified previous manic or mixed episode
•
Be currently treated
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.